NIAID is focused on discovery and development of novel and more effective therapies that can extend and improve the quality of life for people infected with HIV/AIDS and associated co-infections and complications, including strategies for potential eradication or sustained remission of HIV infection. The goal is to identify new drugs that are less toxic with fewer side effects, promote better adherence, and are readily accessible, particularly in resource-limited settings. Promising medicines are tested in human clinical trials to determine whether they are safe and effective.
Several therapeutic agents have been developed to treat HIV and its co-infections and to prevent the transmission of HIV. However, the emergence of drug resistance and the need for simpler regimens that allow better adherence mandate research for better treatments that can improve patient outcomes and control the epidemic. NIAID’s HIV/AIDS therapeutics research agenda is guided by the National Institutes of Health (NIH) Office of AIDS Research, the entity responsible for the overall scientific, budgetary, legislative, and policy elements of all AIDS research sponsored by NIH. The major areas of research within NIAID's therapeutic research agenda include:
Last Updated July 23, 2015